USPTO Examiner HUTSON RICHARD G - Art Unit 1652

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18660667DNA POLYMERASE MUTANT SUITED TO NUCLEIC ACID AMPLIFICATION FROM RNAMay 2024April 2025Allow1110YesNo
18628140ENGINEERED GLUCOSYLTRANSFERASESApril 2024April 2025Allow1211YesNo
18393303CASZ COMPOSITIONS AND METHODS OF USEDecember 2023December 2024Abandon1211NoNo
18569989ENZYMATIC METHOD FOR THE PRODUCTION OF L-GLUFOSINATE P-ALKYL ESTERSDecember 2023June 2025Allow1831YesNo
18521466POLYMERASE COMPOSITIONS AND KITS, AND METHODS OF USING AND MAKING THE SAMENovember 2023April 2025Allow1711YesNo
18478512TELA VARIANTS, COMPOSITIONS, AND METHODSSeptember 2023April 2024Allow621YesNo
18476104MUTANT POLYMERASES AND USES THEREOFSeptember 2023January 2025Allow1611YesNo
18472046Compositions and Methods Related to Nucleic Acid SynthesisSeptember 2023April 2025Abandon1920NoNo
18464955POLYMERASE MUTANTS AND USE WITH 3'-OH UNBLOCKED REVERSIBLE TERMINATORSSeptember 2023February 2024Allow510NoNo
18462868Vaccinia Capping Enzyme Compositions and MethodsSeptember 2023January 2025Allow1711YesNo
18365105EVOLUTION OF PROTEASESAugust 2023May 2025Abandon2121NoNo
18219045MUTANT DNA POLYMERASE(S) WITH IMPROVED STRAND DISPLACEMENT ABILITYJuly 2023December 2024Allow1711YesNo
18343131DNase VariantsJune 2023May 2024Allow1011YesNo
18343727PROCESSES FOR PRODUCING REDUCED COENZYME Q10June 2023November 2024Allow1731YesNo
18195702T4 DNA Ligase Variants with Increased Resistance to SaltMay 2023May 2025Allow2411YesNo
18298291Compositions and Analysis of Dephosphorylated OligoribonucleotidesApril 2023October 2024Allow1941YesNo
18130012Process of Probe qPCR Using Taq DNA Polymerase MutantsApril 2023June 2024Allow1440YesNo
18129292Protein Enriched Microvesicles and Methods of Making and Using the SameMarch 2023February 2025Allow2311YesNo
18191774ALDEHYDE DEHYDROGENASE VARIANTS AND METHODS OF USING SAMEMarch 2023March 2025Allow2421YesNo
18125661NOVEL REVERSE TRANSCRIPTASES AND USES THEREOFMarch 2023April 2024Allow1301YesNo
18176502COMPOSITIONS AND METHODS FOR ENHANCING REVERSE TRANSCRIPTASE ACTIVITY AND/OR REDUCING THE INHIBITION OF REVERSE TRANSCRIPTASEMarch 2023February 2025Allow2311NoNo
18160952ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORSJanuary 2023August 2024Allow1821YesNo
18160951ENGINEERED POLYMERASES WITH REDUCED SEQUENCE-SPECIFIC ERRORSJanuary 2023January 2024Allow1211YesNo
18154437METHOD FOR ADDING CAP STRUCTURES TO RNA USING IMMOBILIZED ENZYMESJanuary 2023March 2025Abandon2601NoNo
18069898CAS9 PROTEINS INCLUDING LIGAND-DEPENDENT INTEINSDecember 2022April 2025Allow2821YesNo
18080926MODIFIED �-GALACTOSIDASEDecember 2022October 2024Abandon2211NoNo
18055966DP04 POLYMERASE VARIANTS WITH IMPROVED ACCURACYNovember 2022April 2025Abandon2921NoNo
18048388MODIFIED THERMOCOCCUS POLYMERASESOctober 2022July 2024Allow2111YesNo
17936144High Throughput Reaction AssemblySeptember 2022May 2024Allow2010YesNo
17935406POLYMERASE COMPOSITIONS & METHODSSeptember 2022July 2024Allow2211YesNo
17935521CASZ COMPOSITIONS AND METHODS OF USESeptember 2022October 2024Abandon2511NoNo
17910349ENZYMES WITH IMPROVED THERMOSTABILITY FOR THE DEGRADATION OF PLASTIC PRODUCTSSeptember 2022June 2025Abandon3311NoNo
17896147ALPHA-AMYLASE VARIANTSAugust 2022May 2024Allow2011NoNo
17894854POLYMERASE MUTANTS AND USE WITH 3'-OH UNBLOCKED REVERSIBLE TERMINATORSAugust 2022July 2023Allow1111YesNo
17808128ENGINEERED DEAMINASESJune 2022July 2024Allow2511NoNo
17841429METHODS FOR GENOMIC INTEGRATION IN PICHIA AND OTHER HOST CELLSJune 2022August 2024Allow2620YesNo
17838852IMMOBILIZED POLY(N)POLYMERASEJune 2022April 2024Abandon2201NoNo
17743859COMPOSITIONS AND METHODS FOR IDENTIFYING RNA BINDING POLYPEPTIDE TARGETSMay 2022November 2023Allow1811YesNo
17742033Thermostable Variants of T7 RNA PolymeraseMay 2022May 2024Allow2421YesNo
17735129ASPERGILLUS ORYZAE AND ITS APPLICATIONMay 2022June 2024Allow2510YesNo
17728573GLYCOSYLATED LYSOSOMAL PROTEINS, METHOD OF PRODUCTION AND USESApril 2022November 2024Allow3121YesYes
17725369POLYMERASE COMPOSITIONS AND METHODS OF MAKING AND USING SAMEApril 2022September 2024Allow2931YesNo
17724342GRIFFITHSIN MUTANTSApril 2022April 2025Allow3630YesNo
17705020ENGINEERED POLYMERASESMarch 2022November 2024Allow3241YesNo
17705043ENGINEERED POLYMERASESMarch 2022July 2024Allow2740YesNo
17678369NOVEL CRISPR-ASSOCIATED (CAS) PROTEINFebruary 2022November 2023Allow2101YesNo
17677655T4 DNA Ligase Variants with Increased ThermostabilityFebruary 2022August 2023Allow1820YesNo
17676546TYPE II CRISPR/CAS9 GENOME EDITING SYSTEM AND THE APPLICATION THEREOFFebruary 2022September 2024Allow3121YesNo
17675278T4 DNA Ligase Variants with Increased Resistance to SaltFebruary 2022May 2023Allow1511YesNo
17673279PROGRAMMABLE DNA-GUIDED ARTIFICIAL RESTRICTION ENZYMESFebruary 2022April 2024Abandon2611YesNo
17586234METHOD FOR ENHANCING PRODUCTION OF HOMEOPROTEIN USING INHIBITOR OF LYSOSOMAL FUNCTIONJanuary 2022July 2024Allow2921YesNo
17625395BIOTECHNOLOGICAL PRODUCTION OF DIOLSJanuary 2022February 2025Allow3720YesNo
17564500ENGINEERED POLYMERASES FOR IMPROVED SEQUENCINGDecember 2021October 2023Allow2210NoNo
17623542GENETICALLY MODIFIED MICROORGANISM AND METHOD FOR PRODUCING DIAMINE COMPOUNDDecember 2021May 2025Abandon4111NoNo
17563794PREPARATION METHOD OF HIGH-STABILITY SUPEROXIDE DISMUTASE WITH TRANSMEMBRANE CAPABILITYDecember 2021December 2023Allow2311YesNo
17645146POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAMEDecember 2021February 2025Allow3851YesNo
17554012Compositions and Methods Related to Nucleic Acid SynthesisDecember 2021June 2023Allow1801YesNo
17553455KETOREDUCTASE POLYPEPTIDES FOR THE SYNTHESIS OF CHIRAL COMPOUNDSDecember 2021May 2025Allow4141YesNo
17544668GLUCOAMYLASES AND METHODS OF USE, THEREOFDecember 2021January 2024Abandon2620NoNo
17595643LINALOOL SYNTHASESNovember 2021February 2025Allow3911YesNo
17531220DNase VariantsNovember 2021April 2023Allow1711YesNo
17523670RECOMBINANT POLYMERASES FOR INCORPORATION OF PROTEIN SHIELD NUCLEOTIDE ANALOGSNovember 2021September 2023Allow2211YesNo
17514043BIOSYNTHESIS OF VANILLIN FROM ISOEUGENOLOctober 2021January 2025Abandon3910NoNo
17500831MODIFIED ENZYMESOctober 2021December 2023Allow2611YesNo
17485606METHOD OF SCREENING INHIBITOR OF CASPASE ACTIVITY BY LIPOPOLYSACCHARIDESeptember 2021January 2024Allow2730YesNo
17485004MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUESSeptember 2021August 2024Allow3531YesYes
17437566PROCESS FOR PRODUCING A FERMENTATION BROTHSeptember 2021July 2024Allow3521YesNo
17470557Taq DNA Polymerase Mutants for Probe qPCRSeptember 2021March 2023Allow1821YesNo
17410647MODIFIED POLYMERASES FOR IMPROVED INCORPORATION OF NUCLEOTIDE ANALOGUESAugust 2021June 2022Allow1021YesNo
17373314METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDSJuly 2021December 2024Abandon4132NoNo
17421967RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF L-DOPA, DOPAMINE, S-NOROCLAURINE OR DERIVATIVES THEREOFJuly 2021March 2025Allow4411YesNo
17419091Phospholipase C Mutant With High Enzyme ActivityJune 2021September 2024Allow3811YesNo
17357442Methods and Compositions for Increased Capping Efficiency of Transcribed RNAJune 2021December 2023Abandon3011NoNo
17355668ENZYME-PORE CONSTRUCTSJune 2021August 2023Allow2611YesNo
17348127Vaccinia Capping Enzyme Compositions and MethodsJune 2021June 2023Allow2411YesNo
17338842ENGINEERED GLUCOSYLTRANSFERASESJune 2021December 2023Allow3011NoNo
17303445MUTANT POLYMERASES AND USES THEREOFMay 2021August 2023Allow2611YesNo
17327750Reactive persulfides mediate sulfur respiration in mitochondria via sulfide:quinone oxidoreductaseMay 2021July 2024Abandon3820YesNo
17319849NOVEL CRISPR-ASSOCIATED (CAS) PROTEINMay 2021November 2023Allow3011YesNo
17317721THERMOSTABLE TERMINAL DEOXYNUCLEOTIDYL TRANSFERASEMay 2021June 2024Allow3741YesNo
17302621POLYMERASE COMPOSITIONS AND KITS, AND METHODS OF USING AND MAKING THE SAMEMay 2021August 2023Allow2821YesNo
17291272A NOVEL CLASS OF PIGMENTS IN ASPERGILLUSMay 2021September 2024Abandon4001NoNo
17244089Efficient Production of Steviol Glycosides in Recombinant HostsApril 2021June 2023Abandon2501NoNo
17227771Use of PolypeptideApril 2021January 2024Abandon3320NoNo
17225189DIMERIC REVERSE TRANSCRIPTASEApril 2021July 2023Allow2811YesNo
17222368Use of PolypeptideApril 2021October 2023Abandon3020NoNo
17221053POLYMERASESApril 2021April 2023Abandon2501NoNo
17217752MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTIONMarch 2021February 2024Abandon3421NoNo
17280792FRUCTOSE-C4-EPIMERASE AND METHOD OF PRODUCING TAGATOSE USING THE SAMEMarch 2021February 2023Allow2320YesNo
17280181ALDEHYDE DEHYDROGENASE VARIANTS AND METHODS OF USING SAMEMarch 2021January 2023Allow2211YesNo
17211595NOVEL REVERSE TRANSCRIPTASES AND USES THEREOFMarch 2021December 2022Allow2101YesNo
17208286DNA POLYMERASE MUTANTS HAVING ENHANCED TEMPLATE DISCRIMINATION ACTIVITYMarch 2021May 2023Abandon2641YesNo
17199343MODIFIED DNA POLYMERASES FOR IMPROVED AMPLIFICATIONMarch 2021April 2023Allow2511YesNo
17274667MUTANT DNA POLYMERASE(S) WITH IMPROVED STRAND DISPLACEMENT ABILITYMarch 2021April 2023Allow2521YesNo
17191141RECOMBINANT POLYMERASES FOR IMPROVED SINGLE MOLECULE SEQUENCINGMarch 2021April 2023Allow2511YesNo
17188764METHODS AND COMPOSITIONS FOR GENOME ENGINEERINGMarch 2021August 2023Abandon3011NoNo
17271439Production Of Non-Native Monounsaturated Fatty Acids In BacteriaFebruary 2021October 2024Allow4321YesNo
17270691MODULATORS OF CAS9 POLYPEPTIDES AND METHODS OF USE THEREOFFebruary 2021October 2024Allow4311YesNo
17181230MODIFIED TYPE A DNA POLYMERASESFebruary 2021November 2022Allow2011YesNo
17181787POLYMERASE ENZYMEFebruary 2021January 2025Abandon4711NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUTSON, RICHARD G.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
26
Examiner Affirmed
14
(53.8%)
Examiner Reversed
12
(46.2%)
Reversal Percentile
67.7%
Higher than average

What This Means

With a 46.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
174
Allowed After Appeal Filing
46
(26.4%)
Not Allowed After Appeal Filing
128
(73.6%)
Filing Benefit Percentile
35.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HUTSON, RICHARD G - Prosecution Strategy Guide

Executive Summary

Examiner HUTSON, RICHARD G works in Art Unit 1652 and has examined 1,131 patent applications in our dataset. With an allowance rate of 57.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner HUTSON, RICHARD G's allowance rate of 57.9% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HUTSON, RICHARD G receive 2.44 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HUTSON, RICHARD G is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +51.7% benefit to allowance rate for applications examined by HUTSON, RICHARD G. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.4% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.4% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 92.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.0% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 63.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.9% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.8% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.